Politics · India Bureau
India's drug regulator flags Abhayrab rabies vaccine batch as substandard
A batch of the widely-used Abhayrab rabies vaccine has been flagged by India's drug regulator as substandard following failed potency testing. The development raises concerns about vaccine quality amid continued reliance on the immunisation across the country.
LSN India ·
India's pharmaceutical regulatory authority has identified a batch of Abhayrab rabies vaccine as failing potency standards, according to official government documentation reviewed by this news service. The batch in question did not meet required efficacy benchmarks during laboratory testing, prompting classification as substandard and potentially spurious.
Abhayrab is among the most commonly administered rabies vaccines across India, used in post-exposure prophylaxis protocols for suspected rabies cases. The vaccine's widespread distribution across public and private healthcare facilities underscores the significance of the quality concern.
The potency test failure represents a critical quality control lapse in a vaccine essential for preventing one of the world's most lethal diseases. Rabies remains a significant public health challenge in India, with thousands of suspected cases reported annually and high mortality rates when post-exposure treatment is delayed or inadequate.
Government health authorities have not yet issued a public advisory regarding the affected batch. The regulatory action highlights ongoing scrutiny of pharmaceutical manufacturing standards and quality assurance mechanisms within India's vaccine production sector.